IP Library › Granted Patent US 8,389,541
Granted Patent B2
US 8,389,541 · App. 13/341,604 · Granted Mar 5, 2013

Inhibitors of protein tyrosine kinase activity

Inventors: Stephen William Claridge (Montreal, CA); Ljubomir Isakovic (Beaconsfield, CA); Michael Mannion (Montreal, CA); Stephane Raeppel (St. Lazare, CA); Oscar Mario Saavedra (Montreal, CA); Frederic Gaudette (Laval, CA); Lijie Zhan (Montreal, CA); Arkadii Vaisburg (Kirkland, CA)
Assignee: MethylGene Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,389,541
App. No.
13/341,604
Granted
Mar 5, 2013
Kind
B2
Abstract

This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Claims (16)

1. A method of inhibiting solid tumor growth in a patient in need thereof, the method comprising administering to said patient a therapeutically effective amount of a compound having the structure:

or a composition, pharmaceutically acceptable salt, racemic mixture , scalemic mixture, diastereomer or enantiomer thereof.

2. The method according to claim 1 , wherein the compound has the structure:

3. The method according to claim 1 , wherein the compound has the structure:

4. The method according to claim 1 , wherein the compound has the structure:

5. The method according to claim 1 , wherein the compound has the structure:

6. The method according to claim 1 , wherein the compound has the structure:

7. The method according to claim 1 , wherein the compound has the structure:

8. The method according to claim 1 , wherein the compound has the structure:

9. The method according to claim 1 , wherein the compound has the structure:

10. The method according to claim 1 , wherein the compound has the structure:

11. The method according to claim 1 , wherein the compound has the structure:

12. The method according to claim 1 , wherein the compound has the structure:

13. The method according to claim 1 , wherein the compound has the structure:

14. The method according to claim 1 , wherein the compound has the structure:

15. The method according to claim 1 , wherein the compound has the structure:

Assignments (2)
CHANGE OF NAME Recorded Oct 11, 2022
From: METHYLGENE INC.
To: METHYLGENE ULC
Reel/Frame 061375/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: METHYLGENE ULC
To: MIRATI THERAPEUTICS, INC.
Reel/Frame 061375/0825 →
Continuity (3)
Division 12200939 · Aug 29, 2008
Provisional Application 60968673 · Aug 29, 2007
Related Publication 20120108628A1 · May 3, 2012